MX342104B - Derivados de cicloalquenil arilo para inhibidor de cetp. - Google Patents

Derivados de cicloalquenil arilo para inhibidor de cetp.

Info

Publication number
MX342104B
MX342104B MX2013011855A MX2013011855A MX342104B MX 342104 B MX342104 B MX 342104B MX 2013011855 A MX2013011855 A MX 2013011855A MX 2013011855 A MX2013011855 A MX 2013011855A MX 342104 B MX342104 B MX 342104B
Authority
MX
Mexico
Prior art keywords
aryl derivatives
cetp inhibitor
cycloalkenyl aryl
derivatives
cholesterol
Prior art date
Application number
MX2013011855A
Other languages
English (en)
Other versions
MX2013011855A (es
Inventor
Lee Seohee
Oh Jungtaek
Lee Jaekwang
Lee Jaewon
Bae Suyeal
Ha Nina
Lee Sara
Original Assignee
Chong Kun Dang Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Pharmaceutical Corp filed Critical Chong Kun Dang Pharmaceutical Corp
Publication of MX2013011855A publication Critical patent/MX2013011855A/es
Publication of MX342104B publication Critical patent/MX342104B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • C07D263/24Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • C07D263/22Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con derivados de cicloalquenil arilo, isómeros de los mismos, sales farmacéuticamente aceptables de los mismos, hidratos de los mismos, o solvatos de los mismos; un método para preparar los derivados; y composiciones farmacéuticas que contienen los mismos. Los compuestos de la presente invención muestran el efecto de la inhibición de la actividad de CETP. Esto significa que los compuestos pueden incrementar el HDL-colesterol y hacer disminuir el LDL-colesterol.
MX2013011855A 2011-04-12 2012-04-12 Derivados de cicloalquenil arilo para inhibidor de cetp. MX342104B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110033943 2011-04-12
PCT/KR2012/002739 WO2012141487A2 (en) 2011-04-12 2012-04-12 Cycloalkenyl aryl derivatives for cetp inhibitor

Publications (2)

Publication Number Publication Date
MX2013011855A MX2013011855A (es) 2013-11-01
MX342104B true MX342104B (es) 2016-09-13

Family

ID=47009830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011855A MX342104B (es) 2011-04-12 2012-04-12 Derivados de cicloalquenil arilo para inhibidor de cetp.

Country Status (17)

Country Link
US (1) US9371294B2 (es)
EP (1) EP2697207B1 (es)
JP (1) JP5820056B2 (es)
KR (1) KR101442644B1 (es)
CN (1) CN103502226B (es)
AU (1) AU2012243583B2 (es)
BR (1) BR112013026280A2 (es)
CA (1) CA2829676C (es)
DK (1) DK2697207T3 (es)
ES (1) ES2617221T3 (es)
HR (1) HRP20170422T1 (es)
HU (1) HUE032075T2 (es)
MX (1) MX342104B (es)
PL (1) PL2697207T3 (es)
PT (1) PT2697207T (es)
RU (1) RU2597266C2 (es)
WO (1) WO2012141487A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015009851A (es) * 2013-01-31 2015-10-14 Chong Kun Dang Pharm Corp Compuestos derivados de ciclohexeno sustituidos con biarilos o biarilos heterociclicos como inhibidores de cetp.
WO2016154873A1 (zh) * 2015-03-31 2016-10-06 华为技术有限公司 一种终端设备和拍照的方法
CN107304174B (zh) * 2016-04-21 2019-05-10 沈阳药科大学 N,n-双取代环烯基甲胺类衍生物及其制备方法和应用
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
SI3755703T1 (sl) 2018-02-20 2022-11-30 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamidni derivati in sorodne spojine kot zaviralci HPK1 za zravljenje raka
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
MA54133B1 (fr) 2018-03-08 2022-01-31 Incyte Corp Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CN110759860B (zh) * 2018-07-27 2022-10-14 江苏瑞科医药科技有限公司 一种3-甲酸甲酯-4-甲氧基-5-氰基吡啶的制备方法
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
JP7399968B2 (ja) 2018-09-25 2023-12-18 インサイト・コーポレイション Alk2及び/またはfgfr調節剤としてのピラゾロ[4,3-d]ピリミジン化合物
JP2022543155A (ja) 2019-08-06 2022-10-07 インサイト・コーポレイション Hpk1阻害剤の固体形態

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929094A (en) 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Cetp活性阻害剤として有効な化合物
DK1425270T3 (da) 2001-04-30 2006-07-03 Pfizer Prod Inc Fremgangsmåder og intermediater til fremstilling af 4-aminoquinolin CETP inhibitorer
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
RU2513107C2 (ru) 2005-12-30 2014-04-20 Мерк Шарп И Доум Корп. Ингибиторы сетр
WO2007081569A2 (en) 2005-12-30 2007-07-19 Merck & Co., Inc. Cetp inhibitors
EP1973546B1 (en) * 2005-12-30 2012-06-13 Merck Sharp & Dohme Corp. Cholesteryl ester transfer protein inhibitors
CA2681628C (en) * 2007-03-16 2016-10-18 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
EP2348859B1 (en) * 2008-10-01 2013-12-04 Merck Sharp & Dohme Corp. Prodrugs of oxazolidinone cetp inhibitors

Also Published As

Publication number Publication date
KR101442644B1 (ko) 2014-09-19
US9371294B2 (en) 2016-06-21
CA2829676C (en) 2017-08-22
HUE032075T2 (en) 2017-08-28
EP2697207B1 (en) 2016-12-14
EP2697207A2 (en) 2014-02-19
NZ615071A (en) 2015-05-29
PT2697207T (pt) 2017-02-14
AU2012243583A1 (en) 2013-10-03
EP2697207A4 (en) 2014-11-19
WO2012141487A2 (en) 2012-10-18
JP2014510786A (ja) 2014-05-01
WO2012141487A3 (en) 2013-01-10
HRP20170422T1 (hr) 2017-06-16
MX2013011855A (es) 2013-11-01
AU2012243583B2 (en) 2015-10-22
CN103502226B (zh) 2015-08-19
RU2597266C2 (ru) 2016-09-10
ES2617221T3 (es) 2017-06-15
RU2013145418A (ru) 2015-05-20
BR112013026280A2 (pt) 2024-04-30
KR20120116362A (ko) 2012-10-22
CA2829676A1 (en) 2012-10-18
US20150119376A2 (en) 2015-04-30
JP5820056B2 (ja) 2015-11-24
PL2697207T3 (pl) 2017-08-31
CN103502226A (zh) 2014-01-08
DK2697207T3 (en) 2017-03-27
US20140031335A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
MX342104B (es) Derivados de cicloalquenil arilo para inhibidor de cetp.
PH12019500163A1 (en) Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12016500169A1 (en) Polymorph of syk inhibitors
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
PH12014502733A1 (en) Neprilysin inhibitors
MD20180040A2 (ro) Inhibitori ai virusului hepatic C
MY172924A (en) Neprilysin inhibitors
MY184303A (en) Notch pathway signaling inhibitor compound
PH12016501462A1 (en) Neprilysin inhibitors
MX353190B (es) Derivados de isoquinolina y naftiridina.
MX2016010973A (es) Compuestos de aminocarbonilcarbamato.
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
MX362879B (es) Usos novedosos.
MX2013011333A (es) Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.
PH12015501223B1 (en) Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
MX2016007985A (es) Compuestos de fluorofenilpirazol.
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
IN2013MU03670A (es)
MX2015013551A (es) Sales de amina de pitavastatina farmaceuticamente aceptables.
TN2013000515A1 (en) Notch pathway signaling inhibitor compound

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: CHONG KUN DANG PHARMACEUTICAL CORP.

HC Change of company name or juridical status

Owner name: PANASONIC INTELLECTUAL PROPERTY CORPORATION OF AME

Owner name: HANMI SCIENCE CO., LTD.*

FG Grant or registration